3 months Premium FREE
No credit card. No commitment.
UnitedHealth Group Incorporated
🇺🇸 UNH · NYSE/NASDAQ
Insurance
Price at analysis: USD 404.05 Current price: USD 401.14 * updated every night
Scores
Key Metrics
Powered by EODHDP/E (TTM)
23.1
P/E (Price-to-Earnings)Shows how much investors pay for each $1 of profit. We display the TTM P/E (Trailing Twelve Months) which uses actual earnings from the last 4 quarters. This is more reliable than Forward P/E which uses analyst estimates.
Calculation: 404.05 ÷ 17.52 = 23.1
TTM period through: 2026-09-30
Forward P/E (estimated): 16.6
Based on analyst estimates
Reference: Provider P/E (Trailing): 26.2
Net Debt/EBITDA (TTM)
1.6x
Latest quarter: 6.1x
Net Debt / EBITDAA leverage ratio showing how many years of EBITDA (earnings before interest, taxes, depreciation, and amortization) it would take to repay net debt. EBITDA approximates operating cash generation. Lower ratios (e.g., <3x) are generally safer; higher (e.g., >5x) may indicate more financial risk.
TTM through: 2026-09-30
Latest quarter (2026-09-30): 6.1x
The quarterly value can spike when quarterly EBITDA is very low (e.g., one-time charges).
Quick guide: <2x manageable, >4x can be risky (sector-dependent).
ROE
15.8%
ROE (Return on Equity)A profitability measure: how much profit is generated from shareholders’ equity. Higher isn’t always better if it comes from high debt.
EV/EBITDA
14.7x
EV/EBITDAA valuation ratio that compares total business value (including debt) to EBITDA. Lower can mean cheaper, but context matters.
Dividend Summary
Powered by EODHDDividend Yield (Fwd)
2.23%
TTM: 2.24%
Dividend YieldThe Forward yield (Fwd) shows the next announced annual dividend / current price — what you'd earn going forward. The Trailing yield (TTM) in the tooltip shows dividends actually paid in the last 12 months. Forward is shown as primary because it reflects the company's current commitment to shareholders.
Forward Yield (estimated): 2.23%
Trailing Yield (TTM, last 12 months): 2.24%
Payout Ratio (Fwd)
53.0%
TTM: 51.5%
Payout RatioDividends as a percentage of earnings. The Forward payout (Fwd) uses the announced dividend divided by actual past earnings (TTM) — it tells you if the company can afford what it promised. Very high payouts can be risky, especially if profits fall.
Announced dividend / actual earnings (TTM)
Payout (Fwd): 53.0%
Payout (TTM): 51.5%
Growth Streak
8 yrs
Consec. increases
Div. Growth (5Y)
12.6%
Dividend History
EODHD Dividends API| Status | Type | Decl. Date | Ex-Div Date | Pay Date | Currency | Amount |
|---|---|---|---|---|---|---|
| Forecast* | Quarterly | — | 14 Sep 2027 | — | USD | 2.32 |
| Forecast* | Quarterly | — | 15 Jun 2027 | — | USD | 2.32 |
| Forecast* | Quarterly | — | 09 Mar 2027 | — | USD | 2.21 |
| Forecast* | Quarterly | — | 08 Dec 2026 | — | USD | 2.21 |
| Paid | Quarterly | 12 Aug 2026 | 14 Sep 2026 | 22 Sep 2026 | USD | 2.32 |
| Paid | Quarterly | 03 Jun 2026 | 15 Jun 2026 | 23 Jun 2026 | USD | 2.32 |
| Paid | Quarterly | 25 Feb 2026 | 09 Mar 2026 | 17 Mar 2026 | USD | 2.21 |
| Paid | Quarterly | 07 Nov 2025 | 08 Dec 2025 | 16 Dec 2025 | USD | 2.21 |
* Extrapolated from past dividend history. Not an official announcement — treat as an estimate, not a confirmed date or amount.
Summary
UnitedHealth Group remains a dominant healthcare powerhouse with a rapidly growing and exceptionally well-covered dividend. The recent dismissal of key securities fraud claims and strong Q3 earnings reinforce its quality, but an elevated TTM P/E of 23x makes it a hold. Existing holders should maintain their positions, while new buyers should wait for a better entry point.
Sector Context
UnitedHealth Group is an elite, vertically integrated healthcare insurance and services conglomerate. While the insurance sector's FCF can be distorted by premiums, UNH's robust adjusted operating earnings (15.7% ROE) easily cover its compounding dividend and support heavy share repurchases.
Temporary Opportunity Identified
The stock continues to face pressure from complex DOJ investigations and Change Healthcare cybersecurity liabilities, though recent dismissals of securities fraud claims and positive earnings momentum are alleviating some fears.
📊 Strategy Analysis
- • Exceptional dividend growth profile with a 14.9% 10-year CAGR and a current yield of 2.24%, which is well above its historical average.
- • Strong shareholder return policy, combining a conservative 38.8% TTM payout ratio with substantial share repurchases (4.92% total shareholder yield).
- • Material reduction in legal risks following the September 2026 dismissal of key securities fraud claims and the December 2025 settlement of the Amedisys antitrust suit.
- • Solid fundamental momentum demonstrated by recent earnings beats, improved margins, and a raised 2026 EPS guidance of at least $20.50.
⚠ What to Watch
- • Elevated valuation with a TTM P/E of 23.06x, which sits well above the core dividend value target range of 8-15x.
- • Intense ongoing structural regulatory headwinds, including an active DOJ antitrust probe into its vertical integration and Medicare Advantage rate tightening.
- • Unresolved litigation and financial overhangs stemming from the Change Healthcare cyberattack and DOJ False Claims Act investigations.
📊 Historical Trends (10 Years)
Powered by EODHDThese charts show how key metrics have evolved over the past decade, helping you identify if the company is improving or deteriorating.
Debt Evolution (Net Debt / EBITDA)
Lower values are better. A declining trend indicates the company is reducing its debt (deleveraging).
Revenue & Earnings Growth
Consistent growth in revenueRevenue
The money a company brings in from selling its products or services. It’s the top line before costs. (blue) and earningsEarnings (Profit)
What’s left after expenses. Positive earnings mean the business made a profit; negative means a loss. (green) indicates a healthy business. Look for upward trends and recoveries after temporary dips.
Analysis date: 2026-10-17
Disclaimer: This information is for educational purposes only. Not financial advice.